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Resumo 
Introdução: A fragilidade é uma síndrome geriátrica que resulta do declínio de múltiplos 
sistemas fisiológicos associado ao processo de envelhecimento. Este declínio manifesta-
se como um estado de vulnerabilidade aumentada a outcomes de saúde adversos, sendo 
considerado um forte preditor de incapacidade, dependência, institucionalização e morte. 
A malnutrição tem sido descrita como um fator de risco independente para o 
desenvolvimento da fragilidade. 
Objetivos: O objetivo principal do estudo foi descrever a frequência da fragilidade em 
utentes institucionalizados com doenças neurodegenerativas no momento da admissão 
numa instituição de saúde. Os objetivos secundários foram descrever a frequência da 
desnutrição e avaliar a correlação entre a fragilidade e o estado nutricional. 
Adicionalmente, comparar a frequência da fragilidade e da desnutrição um e três meses 
após a admissão na instituição. 
Métodos: Foi realizado um estudo piloto transversal e observacional. Todos os utentes 
admitidos no Campus Neurológico Sénior com idade ≥ 65 anos e com pelo menos uma 
doença neurodegenerativa foram incluídos. Foram estabelecidos três momentos de 
avaliação: admissão, um e três meses após a admissão. Em cada momento foi realizada 
uma avaliação do estado nutricional, através do Mini Nutritional Assessment (MNA), 
medidas antropométricas e da Edinburgh Feeding Evaluation in Dementia Questionnaire 
(EdFEQ-Q), e uma avaliação da fragilidade, através da Marigliano-Cacciafesta 
Polypathological Scale (MCPS). 
Resultados: Foram incluídos 76 participantes com uma média de idades de 76±6.8 anos. 
As síndromes parkinsónicas foram as doenças neurodegenerativas mais frequentes na 
amostra (82.9%). A frequência da fragilidade foi de 71.1%, sendo que os utentes com 
síndromes parkinsónicas atípicas apresentaram uma frequência superior à dos utentes 
com doença de Parkinson (85.7 e 60%, respetivamente). Nos utentes com demência, a 
frequência da fragilidade foi de 69.3%. A frequência da desnutrição e do risco de 
desnutrição foi de 73.7%. A desnutrição foi mais frequente nos utentes com demência, 
seguidos pelas síndromes parkinsónicas atípicas e pelos doentes de Parkinson (30.8, 21.2 
e 10%, respetivamente). Foram verificadas correlações estatisticamente significativas 
entre todos os parâmetros nutricionais e a MCPS, destacando-se o MNA e a EdFEQ-Q. 
Relativamente à fragilidade, não foram encontradas diferenças estatisticamente 
significativas entre os três momentos de avaliação. Verificou-se uma melhoria 
significativa do estado nutricional (MNA) apenas no grupo das síndromes parkinsónicas 
da admissão para o primeiro momento de reavaliação. 
Conclusões: A prevalência da fragilidade em utentes institucionalizados com doenças 
neurodegenerativas é elevada, bem como a prevalência da desnutrição. A fragilidade e os 
parâmetros de estado nutricional apresentam correlações significativas.  
 
Palavras-chave: Fragilidade; Doenças neurodegenerativas; Estado nutricional; 
Parkinsonismo; Demência   
 
 
  
Abstract 
Introduction: Frailty is a geriatric syndrome defined as a state of increased vulnerability 
to negative health outcomes that is considered the most powerful predictor of disability, 
dependence, institutionalization and death, and so considered a major health burden. 
Malnutrition has been described to be independently associated with frailty. 
Objectives: Primary objective was to describe the frequency of frailty in institutionalized 
patients with neurodegenerative disorders in the moment of admission. Secondary 
objectives were to describe the frequency of undernutrition and to evaluate the correlation 
between frailty and nutritional status in the moment of admission. Additionally, to 
compare the frequency of frailty and undernutrition one and three months after admission. 
Methods: A cross-sectional observational pilot study was performed. All patients aged 
65 years and older with at least one neurodegenerative disorder admitted in Campus 
Neurológico Sénior were included. Three assessment moments were established: 
admission, one and three-months after. In each moment a nutritional assessment, through 
the Mini Nutritional Assessment (MNA), anthropometric measurements and the 
Edinburgh Feeding Evaluation in Dementia Questionnaire (EdFED-Q), and a frailty 
assessment, through the Marigliano-Cacciafesta Polypathological Scale, were conducted. 
Results: 76 participants were included with a mean age of 76±6.8 years. Parkinsonian 
syndromes represented 82.9% of the sample. The frequency of frailty was 71.1%. Patients 
with atypical parkinsonism were significantly frailer than patients with Parkinson’s 
disease (PD) (85.7 and 60%, respectively). 69.3% of the patients with dementia were frail. 
The frequency of undernutrition (and risk of) was 73.7%. Although not statistically 
significant, undernutrition was more frequent in dementia syndromes, followed by 
atypical parkinsonism and PD (30.8, 21.2 and 10%, respectively). Significant correlations 
were found between all the nutritional assessment parameters and the MCPS, being the 
strongest with the MNA and the EdFED-Q. In the one and three-months reassessment 
moments, statistically significant differences since the admission regarding the MCPS 
were not found. Statistically significant improvement in nutritional status since the 
admission was found only in the parkinsonian syndrome group one-month after the 
admission. 
Conclusions: The prevalence of frailty in institutionalized patients with 
neurodegenerative disorders is high, along with the prevalence of undernutrition. Frailty 
and nutritional status parameters share significant correlations. 
 
Keywords: Frailty; Neurodegenerative disorders; Nutritional status; Parkinsonism; 
Dementia   
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Introduction 
 
Frailty syndrome – Definition and concept 
The older population is rapidly increasing worldwide, being expected 2000 million 
aged over 60 years by the year 20501. This represents a challenge for societies and 
healthcare systems (especially long-term and social care), mainly due to the emerging 
need to guarantee the health and social-contribution capacity of elders to society, as 
well as to prevent the increased costs of an ageing population1. 
The concept of frailty has evolved since 1988, when being “frail” was synonymous of 
having more than 65 years, dependent on others for activities of daily living (ADL) and, 
frequently, institutionalized (easily confused with functional dependence)2. Definitions 
also evolved since then, and in the last 20 years the concept of frailty and its 
preventability potential grew in popularity in scientific communities1,3. In fact, frailty 
is a long-established clinical expression regarding the outlook and vulnerability of an 
individual4.   
Frailty is a common geriatric syndrome that results mostly from the cumulative decline 
of multiple physiological systems and their reserves associated with the ageing 
process4–9. This progressive and cumulative decline manifests itself as a state of 
increased vulnerability to negative outcomes when facing a stress event (whether is 
endo or exogenous), due to the low ability to regain homeostasis and functional 
abilities4,7,9–12. 
As described by Clegg et al., an apparently insignificant stress event, such as an urinary 
tract infection or the introduction of a new drug, can result in a striking and 
disproportionate response in frail elders4. This response may manifest as abrupt changes 
of functional state (mobility to immobility, postural stability to instability and risk of 
falls, functional independence to dependence) and in the mental state (lucid to delirious, 
confusion, and mental fluctuations)1,4. 
Since frailty is a process that develops over time, Fried et al suggested that it can be 
divided in stages, from robust to end-stage frailty, with different clinical presentations, 
and thus different potential for prevention or treatment (table 1)9. 
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Stage of frailty Characteristics 
Robust 
Resilient 
Rapid recovery from stress events 
Subclinical frailty 
Resilience appearance  
Slowly or incomplete recovery from stress events 
Possibility of adverse consequences 
Early frailty 
Clinical frail appearance 
Low tolerance to stress events 
No disability 
Late frailty 
Frail appearance 
Low tolerance to stress events and very slow recovery 
Disability due to decreased energy and/or strength 
End-stage frailty 
Severely frail appearance 
Weight loss and weakness 
Dependence and high risk of death within 12 months 
Table 1. Stages of frailty progression (adapted from Fried et al9). 
Frequent clinical symptoms of frailty are extreme fatigue, unintended weight loss, 
frequent infections, slow gait, muscle weakness and low energy expenditure1,4,10. 
Balance and gait impairments are considered major features of frailty and risk factors 
for falls4,13. In more severe frail stages, spontaneous falls occur due to impairment of 
postural systems such as vision, balance and strength1,4. The major concern with 
spontaneous falls is that, in addition to the significant decrease in mobility, often they 
repeat overtime and are strongly associated with fear of falling (psychological 
response), and reduced physical activity4. 
Fluctuating confusion, delirium, and impaired awareness are related to frailty due to 
reduced brain function integrity4. These symptoms, frequent in hospitalized and long-
term care elders, may occur as outcomes of frailty after a stress event4,14,15. Another 
fluctuating sign of frailty is disability in patients that fluctuate between days with 
functional independence and days with significant dependence4. 
Frailty is considered the most powerful and strong predictor of disability and poor 
health outcomes such as falls, delirium, dependence, hospitalization, 
institutionalization and death, and so considered a major health burden11,12,16. 
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Disability and comorbidity can coexist with frailty, although these concepts are not 
synonymous10,17. Disability is defined as the difficulty or dependency in ADL regarding 
selfcare or housekeeping and can occur as a consequence of an acute event such as hip 
fracture or stroke, which on this case makes it a risk factor for frailty18. Physical 
disability is frequent in the elderly population (20-30%) and tends to increase over 
ageing18. In late life, disability is mostly an outcome of diseases (comorbidity), 
physiologic alterations of ageing and frailty18. 
On the other hand, comorbidity refers to the concurrent presence of two or more 
diseases18. Is an independent risk factor, along with frailty, for disability, but also a 
contributor to the development of frailty18. 
 
Epidemiology 
Frailty prevalence increases with age1,4,19. Worldwide, is estimated that in elderly 
population aged over 65 years the prevalence of frailty is 7%, while in elderly aged 
over 80 years it increases to 20%8. In general population, 5 to 27% are estimated to be 
frail and 35 to 51% are supposedly in pre-frail stages8. In Japan, the country with the 
highest life expectancy, the general prevalence of frailty is estimated to be 7% and in 
elders over 85 years old is 35%20. 
In health care institutions, such as nursing homes, the prevalence of frailty is expected 
to be higher, since institutionalization is one of the negative health outcomes of frailty21. 
Also, dependency, comorbidities, and malnutrition are frequent in this population21–23. 
Although few studies on this issue had been conducted, and despite the heterogeneous 
results, is estimated that frailty affects nearly half of the residents21. 
It is hypothesized that the accumulation of declines, that happens on frailty, starts its 
development earlier than old age, being influenced by health behaviours, health 
experiences, health exposures, and health events1. Also, the greater predisposition to 
decline results from a cumulative balance between risk and protective behaviours, 
experiences, and exposures1. From this point of view, acting to prevent frailty must be 
a continuous trajectory that starts early in life1. 
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Physiopathology of frailty 
The physiopathology of frailty is a complex multifactorial process that involves the 
decline on many physiological systems that collectively increase vulnerability to, 
apparently small, health status changes and/or minor stress events that include minor 
infections and surgeries, and the introduction of a new medication1,4. The stress event, 
as small as it can seem, can result in a sudden and disproportionate change in global 
health status such as from independent to dependent or from lucid to delirious4. 
Is generally accepted that frailty is a dynamic process, whose natural course is 
deteriorating over the ageing process (a major and irreversible contributor to frailty 
development)1,4,12. The ageing process per se is accompanied by changes in sensory 
abilities (such as hearing and vision), sleeping disorders, and urinary dysfunction, that 
can lead to social isolation, falls and poor quality of life1.  
The best studied body components related to frailty development and ageing are the 
brain, endocrine and immune systems, and skeletal muscle, that are intrinsically inter-
related4. Additionally to other physiological systems, such as respiratory or 
cardiovascular systems, also nutritional status is believed to be strongly associated with 
frailty4.  
The brain suffers structural and physiological changes while ageing4,24. This changes 
are most evident on the hippocampus, which seems to be a key component on the 
development of cognitive decline and dementia4. Observational studies have been 
supporting an independent association between frailty and dementia4,25,26. Cognitive 
impairment (CI) can lead to nutritional problems, behaviour changes and falls, 
becoming an important component to assess regarding frailty1,27–29. 
Also, depression in elderly may be underdiagnosed and is strongly associated with 
frailty1. This condition, malnutrition and physical inactivity are potentially treatable 
contributor factors for frailty1. 
With ageing, the immune system tends to fail on to properly respond to acute 
inflammation. Inflammation highly contributes to increase the energy requirements and 
catabolism of skeletal muscle and fat mass, leading to anorexia, weight loss, weakness 
and undernutrition – characteristics of frailty4.  
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Elderly patients are more vulnerable to malnutrition compared to general population1. 
Many factors contribute to this increased risk, including oral and dental health 
problems, reduced appetite, CI, impaired functional ability, and depression1. Weight 
loss and undernutrition are strongly associated with frailty, but unfortunately often 
underdiagnosed1. Sarcopenia is believed to be a major contributor, since it represents 
the progressive loss of muscle mass and strength associated with ageing16. The 
prevalence of sarcopenia can reach up to 50% in the elderly and, not surprisingly, 
usually it anticipates frailty16,30. Changes in the endocrine, immune and brain systems 
can affect the development of sarcopenia, that is also associated with physical inactivity 
and inadequate nutrition4.  
Although frailty is not synonymous of comorbidity, many frail elderly experience 
multiple chronic conditions such as diabetes, chronic renal failure, and osteoporosis, as 
well as neurodegenerative disorders1,31. Along with comorbidity, frail elderly often 
have multiple medications prescribed by different health providers with associated risks 
of drug interactions and adverse side effects1,31. More than 50% of older adults have a 
concomitant intake of five or more drugs (polypharmacy)31–33. 
Drugs may be seen as potential contributors to frailty31. In fact, polypharmacy is 
associated with increased risk of frailty in older adults not only due to the obvious 
increase of comorbidity with ageing, but also due to the overuse of, sometimes, 
unnecessary medication prescribed by several prescribors31–33. Specifically, 
anticholinergic drugs are associated with frailty, falls, hip fractures and reduced 
independence on ADL31. The overuse of proton pump inhibitors in older patients is 
associated with vitamin B12 deficiency, reduced calcium absorption, hip fractures and 
overall mortality31. 
For all these reasons, polypharmacy should be reduced and the patient’s drug 
prescriptions should be periodically reviewed in order to prevent or manage frailty31. 
In already frail elders, some drugs may be useful strategies to indirectly manage or treat 
frailty by controlling chronic diseases (e.g.: diabetes), sarcopenia and neuroendocrine 
dysfunction (which can lead to anorexia of ageing and undernutrition)31.  
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Despite the complexity, the frailty process can be sensitive to treatment and 
interventions, based on the underlying causes such as social, environmental and 
financial support, medical conditions and medication (polypharmacy), nutrition and 
nutritional status (malnutrition and sarcopenia), cognitive status, functional and 
physical status, mood disorders and sensory abilities1,12. 
 
Frailty models 
There are two main models well accepted in the scientific literature to explain frailty 
and most of its complexity: the cumulative model and the physical model3,34. Both share 
the idea that frailty is not only a multifactorial state of vulnerability that increases the 
risk of several adverse outcomes and death, but also an ageing-changeable individual 
characteristic1. 
The concept of accumulation of deficits, developed by Rockwood et al., proposes that 
frailty should be assessed through multiple dimensions by a quantitative and objective 
estimate of the accumulation of deficits which are clinical conditions and diseases35. 
The core ideas are that (1) frailty is a dynamic state, meaning that it can change over 
the life course, and that (2) frailty underlies the variable vulnerability to negative health 
outcomes in individuals with the same biological age1. The rationale is that with ageing, 
people are more likely to die, but the risk of death is variable between individuals of 
the same age. This variability can be related to the fact that older people are more likely 
to have one or more conditions affecting their general health. The cumulative effect of 
harmful conditions is different between individuals and can influence their likelihood 
of death1,35. 
The physical model, known as Physical Frailty Phenotype (PFP), was proposed by 
Fried et al. and assesses frailty mostly by physical performance, weight loss and 
exhaustion3,10. PFP has proven a high predictive validity and is commonly used in 
clinical practice34. Besides this, the lack on including cognitive, mental health, and 
social domains makes it insufficient according to some researchers34. 
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Diagnosis 
Universal consensus regarding the operational criteria in the different practice settings 
to assess frailty is lacking1,3,34. It seems clear that early interventions may be the key to 
prevent frailty, but also the screening of the potential risk factors becomes crucial1,3. 
 
Assessment tools 
The high prevalence of frailty, its outcomes and its possible preventability became an 
increasing source of interest in geriatric medicine4,34. The early identification of older 
adults at risk of frailty should be included in the routine assessment of patients, allowing 
its early identification and thus to plan an cause/problem-centred personalized 
intervention9,34.  
The primary care is considered the core component of the healthcare system where 
frailty must be first screened in order to apply preventable strategies and/or treatment 
interventions3,34.  
An ideal screening tool should be easy to apply in clinical practice and allow a rapid 
identification of the elders at risk of developing frailty or already frail12. 
Since 1980 the number of publications regarding frailty increased exponentially, as well 
as the number of tools developed to assess it12,34,36.  
A systematic review identified 26 questionnaires and 8 indicators of frailty, from which 
the Frailty Index (FI) created from the cumulative model of frailty, and the gait speed 
showed to be the most useful in routine care in a community perspective1,3,12,34,37. In 
fact, slow walking speed itself has been considered a good indicator of frailty and its 
outcomes, since a gait speed >1.2m/s is associated with high life expectancy and <1m/s 
with frailty, disability, and decreased survival19.  
In the FI, deficits on physical, cognitive, mental and functional domains are measured 
and summed34,35. The time consuming and difficulty to implement on daily clinical 
practice are disadvantages of this tool34. 
Besides this, the PFP is the most used and cited instrument to assess frailty, mainly in 
community-dwelling settings, followed by the FI, the Gill Frailty Measure, the Frailty 
Assessment, and the Clinical Frailty Scale (CFS)1,3,12,38. 
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According to the PFP, the presence of at least three of the following condition leads to 
the diagnose of frailty4,10: 
1. Unintended weight loss of 4.5kg or >5% over one year 
2. Slow gait speed according to standardized cut off values for gender and height 
3. Self-reported exhaustion from the Center for Epidemiological Studies 
depression (CES-D) scale (3-4 days per week or most of the time) 
4. Low energy expenditure or low physical activity (according to the modified 
Minnesota leisure time activity questionnaire: <383kcal/week and 
<270kcal/week for men and woman, respectively) 
5. Weak hand grip strength stratified for gender and body mass index (BMI) 
When less than three of the described criteria are present, the prefrail diagnostic should 
be considered10. 
To assess all these diagnostic criteria, the elder must be able to comply, relatively well 
(both physical and mentally), to perform the required tasks, and so the validation study 
performed by Fried et al. included a list of exclusion criteria such as Parkinson’s disease 
(PD), stroke, history of depression, and CI10,17.  For these reasons, the PFP has been 
tested mostly in older adults with a relatively good health status and in community-
dwelling settings17,34,38,39.  
A cross-sectional study from Joanna B. et al., examined the usefulness and diagnostic 
limitations of the PFP when applied to a geriatric subacute ward. From a sample of 500 
elders with a wide range of comorbidities, 35% of the sample were not able to complete 
the assessment on one or more components mainly due to physical or CI, and thus not 
diagnosed17. This group, compared with the group that performed the all five 
assessments, were older, had higher prevalence of dementia, lower BMI, and more 
functional dependent17. In conclusion, the application of this instrument in elders with 
multiple comorbidities, including functional and CI, may be a challenge yet useful 
despite the diagnostic limitations4,17. Further studies on the need to adjust the 
assessment instruments to the different population characteristics would be useful17. 
The FI compiles impairments in domains such as cognitive status, mood, motivation, 
mobility, balance, bowel and bladder function, nutrition, social resources, and others, 
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in a total of 70 items35,40. Due to the high extend of this instrument, the CFS was created 
as a short version, 7-point scale from the original 70 items40,41. Based on the FI score, 
the elders can be classified from fit to frail with a high predictive value of 
institutionalization and death35,40. 
The CFS is nowadays presented as a 9-item scale that classifies the patient from very 
fit to terminally ill42. 
The PFP and the CFS are considered two short instruments, and therefore timesaving 
in clinical practice, and suitable predictors of mortality in older patients admitted at 
geriatric wards12. The CFS also predicts secondary outcomes such as 
rehospitalization12.  
Most of the validation studies for different instruments to assess frailty excluded 
dementia or CI (assessed by the Mini Mental State Examination (MMSE)) and/or PD40.  
In 2008, Amici and colleagues designed an 11-item scale, the Marigliano-Cacciafesta 
Polypathological Scale (MCPS), that assesses the presence and severity of frailty by 
identifying and classifying the possible severity of disorders related to 11 physiological 
systems (Neurological disorders, cardiopathy, respiratory, renal, and locomotive 
apparatus disorders, sensory deprivation, metabolism and nutritional status, cognitive 
state and mood, peripheral vascular system, oncology, and gastroenteric disorders)5. 
This scale, showed a correlation with the main indices of disability5. Amici et al. applied 
the MCPS to 180 elders with a mean age of 80 years along with assessment of ADL 
(Katz, and Lawton and Brody scales), Barthel index, Global depression scale, MMSE, 
Tinetti test for balance and gait, and Mini Nutritional Assessment (MNA)5. Strong 
correlations between MCPS and these scales were demonstrated, making the MCPS a 
useful tool to assess frailty5. 
 
Frailty and Neurosciences 
Although frailty and neurodegenerative diseases, such as Alzheimer’s disease (AD), 
PD, and amyotrophic lateral sclerosis (ALS), share close concepts including 
vulnerability, susceptibility, and homeostatic reserves, only recently the field of 
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neurology has begun to investigate and document these concepts at a neuronal cells 
level, brain networks, and functions43. 
The concept of frailty can be applied, for example, to try to explain the occurrence of 
psychotic disturbances or sudden worsening of cognitive abilities, when a patient is 
subjected to general anesthesia. This can indicate that some brain components, 
networks, and functions are intrinsically vulnerable and can contribute to the 
individual’s vulnerability to stress events43. 
Also, the concept of reduced physiological reserves that is applied to frailty has been 
used in neurology to explain, for instance, the differences between individuals when 
facing similar brain modifications with ageing and pathologies. This has been mainly 
documented in the cognitive field – cognitive reserve. It has been showed that 
individuals with a higher education have a reduced risk of developing AD, supposedly 
due to having higher reserves. Additionally, individuals with higher reserves have more 
likelihood of maintaining adequate functioning in critical situations such as anesthesia, 
dehydration, and metabolic syndromes, and tolerate a greater amount of structural and 
functional disease-specific pathology (like AD or PD)43.  
Although many operational definitions on frailty have been developed, in clinical 
practice its identification is still not easy or consensual. From the neurology field 
perspective, two features should be considered: cognitive abilities and emotional status. 
Both can affect the individual’s vulnerability and resiliency, leading to an increased 
risk of negative outcomes1. 
Even though the concept of frailty refers mainly to the physical components, the CI has 
been proposed as a potential contributor to the vulnerability of older adults and also a 
strong and independent predictor of increased risk of mortality, disability, 
institutionalization, and physical frailty, independently from the clinical diagnosis44. 
The association between CI and frailty could be explained by the interference of 
declined cognitive abilities in the (1) adherence to health interventions, (2) on 
maintaining a healthy lifestyle, and (3) recognizing signs and symptoms of diseases. 
Also, CI can limit planning and the implementation of strategies or adaptive behaviours 
to respond to stress events43. 
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All these reasons justify the inclusion of CI as a key component of frailty1. On the other 
hand, if CI is detected too late, and neurodegeneration has already occurred, there may 
be no preventive or modifiable intervention that could modify the progression to 
dementia and/or frailty43. This makes its implementation controversial. 
Nevertheless, the concept of “cognitive frailty” has emerged as a “heterogeneous 
clinical manifestation characterized by the simultaneous presence of both physical 
frailty and CI”1,44. This condition shares the same rationale of physical frailty (reduction 
in cognitive/brain reserves), and is characterized by the presence of two core features: 
presence of both physical frailty and CI, and no diagnostic of other dementia syndromes 
(such as AD and other dementias)1,44. The CI should be diagnosed by a score of 0.5 on 
the Clinical Dementia Rating Scale (CDR)45. 
Cognitive frailty can negatively influence the health outcomes in physical frail elders1. 
When assessing frailty, the emotional status also requires consideration, since anxiety 
or depression, and other emotional responses, have well-established interactions with 
the nervous, endocrine and immune systems, and can trigger the onset and increase the 
severity of medical conditions. Also, emotional dysregulation can influence the 
adoption of unhealthy behaviors, increasing the risk of developing consequent diseases 
and reducing the compliance to interventions43. 
Emotional disturbances are potentially treatable with pharmacological but also non-
pharmacological interventions (such as psychotherapy) and, therefore, a potentially 
modifiable contributor to frailty43. 
The major features of frailty and neurodegenerative diseases, such as PD and dementia 
syndromes, share common symptoms such as balance and gait impairments, delirium, 
fluctuating confusion and impaired awareness, and disability that fluctuates over 
time1,10,46,47. For these reasons, it seems reasonable to hypothesize that the prevalence 
of frailty in this population is high1,10,46,47.  
Evidence of the prevalence of frailty in PD is lacking, possibly because most studies on 
frailty exclude PD48. Frailty and PD share the appearance of physical vulnerability and 
thus, in clinical practice, the presence of frailty can be misinterpreted as a functional 
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decline48. In a small sample of 49 ambulatory elders with PD, 16 were frail and were at 
a more advanced stage of the disease48. 
The concept of dementia is defined as a clinical syndrome characterized by a global CI, 
memory decline and impairment of, at least, one other cognitive domain (executive 
function or language, for instance)29. For a patient to be diagnosed with dementia there 
must exist a decline from the previous level of cognitive functioning, associated with 
functional impairment and frequently with mood and behaviour changes29,49. AD 
represents the most common type of dementia syndrome (at least 50% of the cases), 
although other conditions can cause dementia such as vascular lesions (vascular 
dementia), Lewy body disorders such as dementia associated with PD and Lewy body 
dementia (LBD), and frontotemporal dementia (FTD)49. Delirium, infections, both 
urinary and faecal incontinence, and constipation are frequent in dementia syndromes26. 
The clinical course of advanced dementia include complications such as pneumonia 
and eating problems, that are associated with high 6-month mortality rates50.  
The prevalence of dementia is increasing, causing a high burden on patients, families 
and societies26,29,51. It is estimated that 32% of AD elders (mild to moderate) living in 
the community are frail, although more advanced stages of the disease and a higher 
dependency should be factors that increase this prevalence52.  
ALS is a fatal and complex motor neuron disease characterized by the progressive 
atrophy of skeletal muscles due to the loss of both upper and lower motor neurons53–55. 
Although the mean age of the onset is 60 years old,  is recently being hypothesized that 
some cases of ALS in older adults are underdiagnosed due to atypical clinical 
presentation, influenced by confusing factors such as comorbidity, weakness, 
dysphagia, muscle atrophy, and frailty55. The prevalence of frailty in ALS patients in 
unknown. 
 
Frailty and other conditions 
Frailty and its association with other diseases have been a source of growing interest 
due to the possible influence of frailty in poor outcomes56. 
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Some of the major preventable chronic respiratory diseases (CRD) such as asthma, 
chronic obstructive pulmonary disease (COPD), and sleep apnea syndrome are strongly 
associated with poor outcomes when frailty is present56. These conditions are associated 
with low quality of life, disability, mortality, and unhealthy ageing by contributing to 
physiological inefficiencies, increased vulnerability to the onset and faster progression 
of diseases, as well as impaired physical and mental performances1.  
COPD is a major source of physical and social disability, and many patients experience 
low body weight and undernutrition1. Also, older adults with COPD seem to have an 
increased risk to develop frailty57. 
Diabetes is a prevalent chronic disease in the elderly that can be inter-associated with 
frailty1,16. In older adults, this metabolic condition can have an impact on physical and 
cognitive function, and quality of life, since usually it coexists with other comorbidities 
such as heart disease, stroke, and other geriatric syndromes that include CI, urinary 
incontinence, pain, and depression1,16. Diabetic elders also have an increased risk of 
developing vascular dementia and AD16. 
Diabetes is thought to more than double the risk of developing frailty, due to accelerate 
the ageing process, to promote sarcopenia, and to contribute to weakness, exhaustion, 
slowness and low physical activity – core components of frailty1,16. 
Although frequently under-considered, oral health problems are common in older 
adults. During ageing, conditions such as tooth loss, the use of dental prostheses, the 
presence of xerostomia, and presbyphagia may occur1. The risk of frailty is higher in 
elders with fewer teeth and that don’t compensate with dental prostheses1. Additionally, 
dental problems are strongly associated with poor nutritional outcomes due to chewing 
and swallowing difficulties leading to weight loss and malnutrition1. 
  
Frailty, Nutritional status and Nutrition 
Nutrition is a key factor and an important health modulator in the older population, 
since an inadequate nutrition contributes to the complexity of frailty’s physiopathology 
and to the development of sarcopenia1,24,58,59.  
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Nutritional status 
The rationale behind the importance of nutrition is simple: it is supposed to provide the 
energy and nutrients needed for the maintenance and correct functioning of all organs 
and vital systems1,24. When nutrition fails to provide the adequate amounts and/or 
quality of nutrients and energy, whether due to inadequate intake, absorption or 
metabolization, the nutritional status can deteriorate causing malnutrition24.  
Undernutrition is defined as a state resulting from a lack on the uptake or intake of 
energy and nutrients, leading to changes on body composition (decreased fat-free 
mass), decrease of physical and mental function as well as impaired clinical outcomes 
from disease (immune dysfunction, more frequent hospitalizations and readmissions)60–
62.  
Although the acknowledged importance of malnutrition (both under and overnutrition) 
to the clinical outcomes, due to the complexity of its aetiology and presentations, a gold 
standard method to assess it is still missing59,63. In 2015, the European Society for 
Parenteral and Enteral Nutrition (ESPEN) published a consensus statement on the 
diagnostic criteria for undernutrition to unify terminologies in clinical practice61. The 
first step to diagnose undernutrition should be to perform a nutritional screening 
through validated tools such as Malnutrition Universal Screening Tool (MUST) or 
MNA61. In those screened as at risk, the undernutrition should be considered in those 
who have one of two conditions: 
1. BMI <18.5kg/m2 or 
2. Unintentional weight loss >10% in an indefinite time or >5% over the last 3 
months plus BMI <20kg/m2 (<70 years old) or <22kg/m2 (≥70 years old) or fat-
free mass index (FFMI) <15kg/m2 in women and <17kg/m2 in men61. 
Despite this, in almost every study published regarding the prevalence of malnutrition, 
the variation of methods to assess it implies a variation of results63,64. This greatly limit 
the data analysis and comparison25. 
Older adults are more vulnerable to malnutrition as they present multiple risk 
factors58,60,63. A systematic review, based on longitudinal data, show that the ageing 
process per se, polypharmacy, frailty, constipation, cognitive decline, dementia, eating 
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dependence, poor appetite, dysphagia, and institutionalization, are risk factors 
highlighted as significant contributors to malnutrition60. The diagnose of PD was also 
a stated risk factor60.  
The decline in functional and cognitive abilities can lead to institutionalization, which 
also increases the risk of malnutrition59,63,65,66.  
Acute and chronic diseases in this population increase even more the risk of 
malnutrition, since the nutritional problems exacerbate, and the nutritional intake is 
often affected58. 
The clinical consequences of malnutrition regarding its relation to poor outcomes are 
well-documented: increased rates of pressure ulcers and infections, increased periods 
of hospitalization, higher mortality, and increased time for convalescence after acute 
illness58. Also, undernutrition is associated with other geriatric syndromes such as 
sarcopenia, insomnia, psychosis, dementia, depression, delirium, and neurological 
disorders58,66. These factors increase the risk of falls and functional dependence66. 
The prevalence of malnutrition in the elderly is heterogeneous and rises as the level of 
care increases58,62,67,68. In community setting, is estimated that malnutrition affects 5 to 
30% of elders, while in residential care facilities it rises to 16 to 70%63.  
Nutritional status and frailty share a close relationship, being estimated that 90% of 
community-dwelling elders at risk of malnutrition are either prefrail or frail69. 
Malnutrition seems independently associated with frailty70.  
It is generally accepted that neurodegenerative disorders, such as dementia, PD and 
ALS, increase the risk of malnutrition71,72. 
In institutionalized elderly, with neurodegenerative disorders, the prevalence of 
undernutrition, at the moment of institutionalization, is 77% according to the MNA and 
46% according to BMI72. 
PD is the second most common neurodegenerative disorder worldwide, being estimated 
that in Portugal 180 of 100.000 inhabitants aged over 50 years old have the disease64,73.  
Lower BMI and unintentional weight loss have been reported as more prevalent in PD 
than aged-match controls. The duration, stage and severity of the disease are associated 
with significant decrease in BMI and body weight64. PD patients present a higher risk 
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of developing sarcopenia. In older adults with idiopathic PD, sarcopenia is common 
(18-41%, depending on the operational criteria) and also associated with disease 
severity74,75. 
Motor symptoms of PD include bradykinesia, rigidity, akinesia, and resting tremor 
which can influence the patients’ ability to shop and cook independently, that lead to 
increased risk of malnutrition64. Also, non-motor symptoms such as constipation, 
dysphagia, olfactory dysfunction, hyposmia, delayed gastric emptying, early satiety, 
sialorrhea, depression, dementia, and apathy, play a significant role on the nutritional 
intake and can contribute to malnutrition64.  
Malnutrition in PD is estimated to affect 0 to 24% of community-dwelling patients, 
while 3 to 60% are considered at risk64. 
Patients with dementia frequently present nutritional problems or disrupting eating 
behaviours that lead to increased risk of malnutrition29. Weight loss is considered an 
important feature of dementia that can begin before the diagnose and becomes more 
frequent with the course of the disease29. The reported prevalence of malnutrition in 
older adults with dementia is 47.8%76. LBD and vascular dementia present a higher 
prevalence of malnutrition in community-dwelling patients (77% and 49% at risk, 
respectively)76. 
In early stages these patients can have problems on planning, shopping, preparing and 
cooking food and meals, and progress to forget to eat or that already ate, apraxia for 
food and/or utensils, eating dependence, behavioural problems such as agitation and 
hyperactivity during meals29. Also, 13 to 57% of the patients develop dysphagia that is 
more common in late stages of FTD and AD29.  
ALS patients present multiple risk factors for malnutrition: dysphagia, anorexia, 
depression, weakness of abdominal and pelvic muscles that prolongs meals time and 
fatigue, constipation, muscle atrophy, and increased energy expenditure by the 
respiratory system53. Malnutrition is considered an independent prognostic factor 
during the follow-up of ALS patients, while weight loss is a prognostic factor both at 
the diagnosis and follow-up53. 
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In many ways, frailty and nutritional status share similar concepts, as the same difficulty 
on standardizing a definition and gold standard methods to assess, widely variation on 
the reported prevalence, and multifactorial aetiology1,61. 
Nutritional status assessment should be a comprehensive and multifactorial approach, 
much as a frailty assessment should be24,29,53,61,77. 
 
Body weight and Body mass index 
Weight loss, low BMI, and undernutrition demonstrate to be important indicators of 
frailty1,78. In fact, weight loss is included in several tools to assess frailty such as the 
PFP78. 
Although much attention is being paid to low BMI and undernutrition, recent studies 
have found a possible association between high BMI and obesity with frailty1,78,79. This 
is particularly important since overweight and obesity prevalence in elderly has been 
increasing over the years and a gradual reduction of skeletal and bone mass can occur 
unnoticed due to high body volume1,78,80–82. Blaum and colleagues were the first authors 
to demonstrate that prefrail and frail women aged over 70 years had a significantly 
higher prevalence of overweight and obesity1,83. 
In Esquinas et al. study, the odds ratio for obesity and abdominal obesity and the risk 
of frailty was 1.73 and 1.67, respectively84. The authors also showed that obesity was 
associated with increased risk of exhaustion, low physical activity, and weakness – 
important components of physical frailty84. 
Studies have shown that the association between BMI and frailty can be translated in a 
U-shaped curve, meaning that both low and high BMI are related to the development 
of frailty1,78. Rietman and colleagues have compared the BMI values in frail elderly in 
different domains such as physical frailty, cognitive frailty, social frailty and 
psychological frailty, and found higher prevalence of physical frailty in BMI under 20 
kg/m2 and over 30 kg/m2. In psychological and social frailty domains, no association 
with BMI was found78. These results were concordant with Hubbard et al. conclusions, 
particularly in relation to BMI, but that there is also a high prevalence of frailty in 
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patients with high waist circumference (≥88 cm for women and ≥102 cm for 
men)78,79,84.  
In obese older adults, the intentional or non-intentional weight loss might have 
unwanted functional effects such as loss of lean and bone mass, which can lead to 
sarcopenia and frailty1,58,85–87. Therefore, it’s extremely important that both nutritional 
and physical interventions have in consideration the goal of, at minimum, to prevent 
the loss of lean mass (preferably to increase)1. The benefits and potential risks of 
promoting these interventions in frail elders to change simultaneous body weight, body 
composition and functional abilities, should be considered1,85–87. 
Although a BMI up to 30kg/m2 is correspondent to being overweight, it has been 
showed to be a protective factor against morbidity and mortality in older adults, so an 
intervention should only be planned aiming weight loss in elderly with BMI > 30kg/m2 
88. In these individuals, maintaining or improving muscle mass should be a major goal 
of the intervention, with greater reach of effectiveness when exercise and nutrition 
interventions are combined1,87. A moderate energy restriction (200-500kcal/day), a 
protein intake of at least 1g/kg body weight/day, and an adequate intake of 
micronutrients, associated with exercise or physical activity to promote a moderate 
weight loss (0.5-1kg/week or 8-10% of initial body weight in a 6 months period) is 
recommended1,85,88. 
BMI, as a single diagnostic criteria for nutritional status is not sensitive to body weight 
changes such as weight loss, so it should be used in combination with other nutritional 
parameters64. 
Weight loss and underweight, as a result of inadequate intake of energy and protein, are 
important contributors to poor nutritional status and decreased reserve capacity6,10,64. 
This weight loss is associated with decrease of skeletal muscle mass, that leads to lower 
muscle strength, exhaustion, reduced physical performance and activity – all considered 
manifestations of physical frailty6. 
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Nutritional assessment tools 
Nutritional status assessment through validated tools is recommended as they include 
multiple domains related to nutritional problems and allow a unify multifactorial 
assessment64,77. 
Regarding neurodegenerative disorders, no specific nutritional assessment tool is 
recommended.  
MNA is validated for older adults independently of the setting (community, nursing 
home or hospital) and is one of the most widely used tools, including for 
neurodegenerative patients29,58,64,89. Nutritional status assessed by the MNA was 
demonstrated to be associated with frailty69,90,91.  
 
Nutrition – a risk factor and a therapeutic intervention  
In the elderly, the main goal of nutrition should be to provide adequate amounts of 
energy, macro and micronutrients, and fluids in order to improve or to maintain an 
adequate nutritional status and to contribute to improve functional capacity and quality 
of life58. 
Nutrition have been evidenced to be an important factor associated with the 
development of both sarcopenia and frailty, as well as a major contributor or influencer 
on many of the components involved on frailty onset and progression1,92. Also, the 
characteristics of frailty have many features that can be related to nutrition, specifically 
to insufficient nutrition: muscle weakness, sarcopenia, and fatigue1,6.  
The contribution of diet to the mechanisms that lead to frailty remains unclear. 
Nevertheless, diet quality, healthy food choices and food diversity are correlated with 
frailty1,36,93.  
Instead of focusing only in specific or single nutrients, the whole dietary pattern should 
be analysed and modified and/or improved regarding preventing or treating frailty1. A 
diet rich in nutrient-dense foods and low on saturated fats seems associated with lower 
risk of frailty1,6,94,95. Such characteristics can be found in the Mediterranean diet (MD). 
MD is characterized by a combination of different types of food and nutrients with 
potential protective effects against chronic and inflammatory conditions30. High intake 
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of sources of polyunsaturated fats (nuts and fish) and fiber (vegetables, fruits and whole 
grains), combined with a moderate intake of dairy products, olive oil (as a source of 
monounsaturated fats) and moderate alcohol consumption are the main features of this 
dietary pattern30,95–98.  
Higher adherence to MD has been inversely associated with functional impairment and 
frailty, as well as a protective dietary pattern against chronic diseases such as diabetes 
and AD30,36,95–99. 
A recent prospective study performed with 560 non-frail French older adults showed 
that the incidence of physical frailty was associated with low adherence to the MD96. 
Also, MD adherence was associated with a significant reduction of the risk of slowness, 
poor muscle strength and low physical activity96. 
 
Energy 
The imbalance between energy intake and expenditure compromises the metabolic 
functioning of physiological systems36. Catabolic response of muscle and fat tissues 
occurs when the energy intake is insufficient to meet energy needs, compromising 
functional abilities and the occurrence of weight loss36. Thus, the maintenance of 
muscle mass highly depends on the energy intake36. 
Older adults often present anorexia of ageing, defined as the loss of appetite associated 
with ageing, that is partially explained by changes in taste and/or smell, slower gastric 
emptying and endocrine dysfunction, chewing and/or swallowing problems, CI, and 
comorbidity that may negatively affect energy and nutrient intake36,100–102. 
The anorexia of ageing is more prevalent in frail elders and is considered a modifiable 
risk factor for frailty36,100–102. 
In 34% of institutionalized older adults the energy intake is lower than the 
recommended6. Frail older adults seem to have insufficient intakes of energy, protein 
and/or other nutrients when compared to non-frail elders1,36.  
A daily energy intake ≤21 kcal/kg body weight/day was found significantly associated 
with frailty in a sample of 802 elders103. In the same sample, the low intake of protein, 
vitamin D, E, C and folate were also associated with higher risk of frailty103. The 
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authors concluded that a low intake of more than three nutrients were independently 
related to the presence of frailty103.  
 
Protein 
The imbalance between protein needs and real intake promotes loss of skeletal muscle 
mass, loss of strength, sarcopenia and physical disability that, in other words, promotes 
frailty36,104. Along with low protein intake, muscle disuse due to bed rest or low physical 
activity leads to a change in the protein synthesis and breakdown and muscle 
atrophy36,104. 
Evidence shows that 35% of institutionalized elderly fail to ensure the minimum protein 
intake to maintain muscle integrity (0.7g/kg/day) due to physiological changes, 
comorbidity, physical and mental disabilities and age- and/or disease-associated 
anorexia36,104.  
Lower incidence of frailty has been observed in older adults with higher protein intake, 
meaning that a possible goal for nutritional interventions on frailty should be to promote 
an adequate intake of protein1,105,106. A French cohort study found significant 
associations between lower prevalence of frailty and a protein intake of 1g/kg body 
weight/day or higher107. 
Besides predicting frailty, low protein intake also predicts low bone mass and 
osteoporosis, that increases two times the risk of developing frailty104. 
The specific role of the source of protein ingestion (animal vs vegetable), specific 
amino acids (AA) or even the timing to consume protein can be relevant factors 
regarding the anabolic effect of protein intake, however few studies have been 
performed so far1. In 2016, a prospective study concluded that the total daily intake of 
protein was inversely associated with the incidence of frailty105.  
To date, only one cross-sectional study found a possible relation between the 
distribution of protein intake during the day and frailty108. In a sample of 194 
community-dwelling elders, the authors found that frail participants had a significant 
lower intake of protein in the morning than the pre-frail and non-frail108. In the same 
study, the total amount of protein intake was found not to be related to frailty108.  
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Micronutrients 
Micronutrient deficiency is common in the elderly109. In Semba et al study, the number 
of micronutrient deficiencies was associated with increased risk of frailty in older 
women, in which each deficiency increased the risk in 10%109. Low intakes of vitamins 
A, C, D, E, B6 and folate have been pointed as related to frailty106. 
The evidence of supplementation of micronutrients is also scarce and heterogeneous, 
as well as little studied besides healthy and non-frail elders or in sarcopenia1.  
 
In conclusion, although is generally accepted that the modification of nutrition quality 
could improve strength, walking speed, and nutritional status of frail elderly, the 
available evidence is limited to ensure this hypothesis and to develop an intervention1. 
Since there is no available guidelines for nutritional intervention specifically in frailty, 
the principles of the nutritional care process for older adults should be applied, namely 
screening, assessment, defining goals, planning and implementing an intervention, 
monitoring, updating goals and intervention, and periodic reassessment58. Nutritional 
therapy in order to improve nutritional status and functional abilities should be 
implemented as a component to the treatment of frailty6,67,105,110.  
 
Nutritional therapy 
Currently, no specific dietary recommendations were published to treat frailty. The 
nutritional therapy in frail older adults should follow similar orientations than those for 
geriatrics, adjusted and individualized regarding nutritional status, physical activity, 
disease and tolerance58. 
The nutritional intervention should aim to provide an energy intake of 30kcal/kg of 
body weight/day58. In ill older adults, a minimal of 27 to 30kcal/kg/day is 
recommended, while for underweight elders it should rise to 32 to 38kcal/kg/day58. 
Protein intake recommendations for both adults and older adults are 0.8-1.0g/kg of body 
weight/day104. However, in 2014, ESPEN highlighted the importance to increase 
protein intake in elders for preservation of lean mass, functionality and general 
health104. 
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The current reccomendations for healthy older adults are 1-1.2g/kg/day, while for older 
adults with acute or chronic diseases the goal should be 1.2-1.5g/kg/day104. 
Institutionalized older adults often present multiple chronic conditions, and thus greater 
protein needs104. In severe illness, injury or malnutrition the daily amount of protein 
can rise up to 2g/kg/day58. Specifically for frailty, the scientific evidence is scarce 
regarding protein intake58. 
Besides the potential, reliable evidence on randomized-controlled trials (RCTs) 
regarding the role of protein intake is scarce, and most of the studies have been focusing 
on sarcopenia or their samples only included healthy elders1.  
The oral nutritional supplements (ONS), namely those rich in energy, protein, and 
micronutrients, seem a promising treatment option for frailty1. These products should 
be provided as treatment options in older adults with malnutrition or at risk of 
malnutrition with chronic conditions, institutionalized or community-dwelled, when 
dietary counselling and food fortification and enrichment are insufficient to reach 
nutritional intervention goals regarding nutritional intake, body weight, and reducing 
the risk of functional decline58. 
The ONS should provide at least 400kcal/day and at least 30g/day of protein in case of 
malnutrition or risk of malnutrition58. The efficacy and benefits of starting ONS should 
be assessed once a month58. 
A systematic review of Cochrane stated that supplementation of energy and protein 
produces small but consistent weight gain in older adults, as well as reduces 
mortality111. However, no evidence was found that ONS improved functional abilities 
or reduced the length of hospitalization111. 
Although the growing evidence of the benefits of ONS in undernourished older adults 
in multiple settings, the currently available evidence regarding these products and the 
treatment of frailty is scarce1,58,112–116. 
Specifically, in institutionalized frail older adults, the research and evidence are little117. 
A small RCT with 50 frail nursing home residents showed high compliance with the 
intake of a ONS during a 10 weeks intervention117. However, no significant increase on 
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the total energy intake was observed and the overall nutritional status or functional 
status didn’t significantly improve117.  
 
Therapeutic interventions 
Frailty is a multifactorial syndrome, which implicates a multidisciplinary approach 
based on individualized and comprehensive assessment of older adults1,118.  
Guidelines to provide a line of treatment or prevention for frailty are currently 
lacking118,119. The main response from the health care systems to frailty is reactive to 
the acute situations such as falls, delirium and immobility119. 
Inadequate nutrition, poor nutritional status, depression, physical inactivity and 
polypharmacy are potentially treatable causes for frailty1,9. 
The combination of adequate nutrition (with or without supplementation) and exercise 
are recommended to improve lean mass, physical performance and to treat/attenuate 
frailty1,120. The combination of nutritional (nutritional supplementation), physical 
(physical training), and cognitive (cognitive training) interventions in frail older adults 
seemed effective in reversing frailty in a sample of community-living elders121. In this 
study, beneficial effects of the interventions were observed after 3 months121.  
Exercise programs improve functional abilities, reduce the risk of falling and increase 
the quality of life of frail older adults122. In older groups, promoting long-term 
adherence is important to promote a regular and feasible training regarding intensity 
and type of exercises122.  Resistance-training should be performed weekly (2-3 times) 
at the beginning and then added power-training to more efficiently improve and 
maintain muscle quality122. Functional abilities should be improved by combining the 
training with ADL stimulation122. Aerobic exercise is also recommended, including 
walking, treadmill, stair climbing and cycling. The exercise programs should always be 
individualized to the elders considering safety, functional and cognitive abilities122. 
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Research objectives 
The primary objective of this research project is to describe the frequency of frailty in 
institutionalized patients with neurodegenerative disorders in the moment of admission 
in a healthcare institution. 
The secondary objectives are: 
a) To describe the frequency of undernutrition and risk of undernutrition in the 
moment of admission 
b) To evaluate the correlation between frailty and nutritional status in the moment 
of admission 
c) To compare the frequency of frailty and undernutrition one and three months 
after admission 
d) To evaluate the correlation between the MCPS and CFS. 
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Methods 
Study design 
A cross-sectional observational pilot study was performed to meet the proposed 
objectives of this study. A component of prospective study design was added to meet 
secondary objectives regarding reassessments of one and three months after admission.   
 
Scientific and Ethics approvals 
The research project was approved by both the Scientific Board of the Faculty of 
Medicine of the University of Lisbon (FMUL) and by the Ethics Committee of Campus 
Neurológico Sénior (CNS) in 21st November 2017 and 1st February 2018, respectively. 
 
Study duration and data collection 
Data collection was performed for 4 months.  
The research units involved were: 
a) CNS, Torres Vedras, Lisbon, Portugal – where participants were recruited, and 
data was collected; 
b) FMUL and Lisbon School of Health Technology, Instituto Politécnico de 
Lisboa (LSHT). 
 
Inclusion and exclusion criteria 
All patients with 65 years and older, with at least one of the following 
neurodegenerative disorders, consecutively admitted in CNS, were screened for 
inclusion and exclusion criteria: 
a) Dementia Syndromes, such as AD, FTD, Vascular dementia (VD) and other 
non-specified dementia syndromes; 
b) Parkinsonian Syndromes, such as PD, LBD, Progressive Supranuclear Palsy 
(PSP), Corticobasal Degeneration (CBD), Multiple System Atrophy (MSA) and 
Vascular Parkinsonism (VP); 
c) Motor Neuron Disease. 
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A written informed consent to participate in the study was provided to all patients who 
meet the inclusion criteria. This consent was obtained from a legal representative if the 
patient had dementia.  
Patients with major lower limbs oedema were excluded due to the risk of overestimating 
anthropometric measurements such as calf circumference. 
 
Outcomes 
The primary outcome is the frequency of frailty according to the MCPS, namely slight, 
medium, medium-severe, severe and very severe frailty in institutionalized patients 
with neurodegenerative disorders in the moment of admission. For purposes of 
statistical analysis the global frequency of frailty is considered the sum of the 
frequencies of medium-severe, severe and very severe frailty from the MCPS. 
The secondary outcomes are: 
a) The frequency of undernutrition according to the Mini Nutritional Assessment 
in the moment of admission. 
b) The correlation between frailty and the different criteria for nutritional status in 
the moment of admission. 
c) The frequency of frailty and undernutrition one and three months after the 
admission. 
d) The correlation between the MCPS and CFS. 
 
Materials 
Information sheet 
An information sheet was prepared to participants, explaining the research project title, 
the purpose of the study, procedures, possible benefits, predictable physical risks, 
voluntary participation and right to drop out, the use of data and investigators contacts 
(annex I). 
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Informed consent  
All participants and/or legal representatives signed an informed consent form. As a 
research unit, CNS has its own institutional informed consent form that is presented in 
the moment of admission by the nurse who receives the patient and/or caregiver (annex 
II). 
 
Case report form  
A case report form (CRF) was developed to collect all the patient-relevant data 
regarding procedures specified by the assessment protocol (annex III). 
 
Statistical analysis 
The distribution of the data was analysed by skewness and kurtosis, and normal 
distribution was considered when the variable followed a symmetric and mesocuric 
presentation. 
All data was analysed using descriptive statistics: categorical variables through relative 
frequencies, and continuous variables through mean and standard deviation.  
The Spearman’s correlation test was used to assess the following correlations: 
a) The correlation between the MCPS and the CFS 
b) The correlation between the CFS and the BMI, mid-arm circumference (MAC), 
calf circumference (CC), MNA, the Edinburgh Feeding Evaluation in Dementia 
Questionnaire (EdFED-Q) and the Subjective Global Assessment (SGA) 
c) The correlation between the MCPS and the SGA 
 
The Pearson’s correlation test was used to assess the following correlations: 
a) The correlation between the MCPS and the Hoehn and Yahr scale (H&Y) 
(severity of parkinsonian syndromes) 
b) The correlation between the MCPS and the CDR (severity of dementia 
syndromes) 
c) The correlation between the MCPS and the BMI, MAC, CC, MNA and the 
EdFED-Q 
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d) The correlation between the H&Y and the MNA, the EdFED-Q and the SGA 
To assess differences between the mean values of independent groups, the Mann-
Whitney test was used for the following variables: age, MCPS score, MNA score, BMI 
value, MAC value, CC value and the EdFED-Q. The difference between median values 
of categorical variables such as the H&Y, the CFS and the SGA were assessed with the 
Chi square test. 
To compare differences between reassessment moments (admission, one and three-
months), the Wilcoxon test for paired samples was used for MCPS and MNA results. 
Statistical significance was considered ≤0.05 for all tests. 
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Assessment protocol  
Assessment moments and timings 
The established moments to perform the assessment protocol were: 
a) In the admission: the assessment protocol was performed by the investigator 
within the first 24-48 hours after the patient was admitted; 
b) One-month reassessment: the first reassessment was performed one month after 
the date of the admission; 
c) Three-month reassessment: the second reassessment was performed three 
months after the date of the admission. 
Each assessment moment was composed by a frailty and a nutritional assessment. 
 
Sociodemographic and clinical data  
Sociodemographic information was collected in the admission. 
The main neurodegenerative disorder diagnosed, and other relevant clinical background 
were collected from the clinical process. Also, the severity of the disease was rated 
according to: 
a) The H&Y for parkinsonian syndromes123 
b) The CDR for dementia syndromes45 
 
Frailty assessment  
There are no specific tools to assess frailty in patients with neurodegenerative disorders. 
As described in the introduction section (sub-section Diagnosis – Assessment tools), 
most of the instruments developed to assess frailty excluded some of the 
neurodegenerative disorders included in the present study, or their results could be 
different when applied to the studied population (e.g.: PFP), or its application was too 
extensive for clinical practice (e.g.: FI). 
The investigators intended to assess frailty with the same instruments, independently 
of the diagnose, and tools were selected following the criteria: 
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Very fit
Well
Managing 
well
Vulnerable
Mildly frail
Moderately 
frail
Severely 
frail
Very 
severely 
frail
Terminally 
ill
1. The structure and content of the scale had to be comprehensive, meaning that 
most of frailty domains should be included (cognitive, mood, physical, 
nutrition, and others) and covered a multidisciplinary assessment 
2. Not too long and time-consuming to apply 
3. Not dependent on the patients’ collaboration (either physical and/or mental) or 
diagnose 
Also, we aimed to apply one of the most used scales to assess frailty.  
 
The Marigliano-Cacciafesta Polypathological Scale 
The MCPS was developed as a new multidimensional tool to assess frailty5. 
The structure and content of MCPS allows its application to all the participants, 
independently of the collaboration or diagnose, while not too extensive to apply on 
clinical practice. Besides its objectivity, the MCPS shares the concept of the FI. 
The obtained classification of frailty is: Slight (<15 scores), Medium (15-24 scores), 
Medium-Severe (25-49 scores), Severe (50-74 scores) and Very severe polypathology 
(≥75 scores)5. 
 
Clinical Frailty Scale 
The CFS is a short instrument of 9-items (figure 1), derived from the FI, which classifies 
frailty according to the following:  
 
 
 
 
 
 
Figure 1. Classification of frailty according to the items of the clinical frailty scale (adapted 
from Rockwood et al124). 
 
 
32 
 
This scale bases its assessment mainly on physical performance, appearance, and 
dependence124. The score is obtained by the health professional perception on the 
patients’ global health/frailty according to the detailed descriptions124.   
 
Nutritional assessment  
There are no specific tools to assess nutritional status in patients with neurodegenerative 
disorders. Nutritional status was assessed according to two validated questionnaires and 
three non-invasive anthropometric measurements. 
 
Mini Nutritional Assessment   
The MNA is a simple and easy to apply questionnaire that assesses nutritional status, 
and more specifically detects undernutrition125,126. This tool is widely used in geriatric 
populations due to its comprehensive assessment, from community-dwelling to 
institutionalized elders125–128. 
MNA is composed of two essential parts: 
a) The screening tool (MNA short-form), that detects the risk of undernutrition 
with six questions regarding recent changes in food intake, recent involuntary 
weight loss, mobility, recent psychological stress or acute disease events, 
neuropsychological problems and low BMI127; 
b) The assessment tool (MNA full form), that assesses more deeply twelve others 
factors that can influence nutritional status such as pressure sores, 
polymedication, nutrient intake, eating dependence, and low MAC and CC127. 
The sum of both parts gives information about the general nutritional status: 
a) Normal nutritional status: 24 to 30 points; 
b) At risk of undernutrition: 17 to 23.5 points; 
c) Undernutrition: <17 points125,127. 
To monitor nutritional status, it is recommended to reapply MNA every three 
months129. 
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Subjective Global Assessment 
The second questionnaire used to assess nutritional status in this research project was 
the SGA130. Although it is not one of the most used tools in the geriatric population, 
SGA performance was considered favourable as a method of nutritional 
assessment128,131.  
The accuracy of this questionnaire has been questioned due to its subjectivity since the 
results depend on the experience of the observer on detecting nutritional changes131. 
Besides this, SGA adds important information to patient’s nutritional status that can 
guide and/or help to focus the nutritional intervention, namely gastrointestinal 
symptoms and severity of recent weight loss132. Another interesting feature of this tool 
is physical examination regarding muscle and fat reserves deficits and fluid status, 
which allows a monitoring of the general body composition through regular 
reassessments. 
SGA rates nutritional status according to three categories: 
 Category A – Well nourished 
 Category B – Moderately (or suspected of being) malnourished 
 Category C – Severely malnourished 
To monitor and to detect changes in nutritional status is recommended to reapply SGA 
monthly133.  
 
Body mass index  
The body weight of all participants was obtained using a calibrated digital chair scale 
SECA134. The height was obtained from official personal identification cards since most 
of the participants couldn’t keep a straight orthostatic position to allow an accurate 
measurement. 
BMI was calculated according to the equation 
𝑊𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)2
.  
The classification of nutritional status according to BMI was the following: 
a) Undernutrition: <22kg/m2; 
b) At risk of undernutrition: 22 to 23.9kg/m2; 
c) Normal nutrition status: 24 to 26.9kg/m2; 
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d) Overweight: 27 to 30kg/m2 for males and 27 to 32kg/m2 for females; 
e) Obesity: >30kg/m2 for males and >32kg/m2 for females135. 
 
Mid-arm circumference  
MAC was measured with a measuring tape on the non-dominant arm in the midpoint 
between the acromion and olecranon136.  
Mid-upper arm circumference percentiles from the Center for Disease Control and 
Prevention (CDC) were used to obtain a classification of nutritional status according to 
gender and age137. The interpretation was the following:  
a) Undernutrition: percentile <15th; 
b) Normal nutritional status: percentile 15 to 75th; 
c) Overweight/Obesity: percentile >75th 138. 
 
Calf circumference 
The measurement of CC was performed in the left leg positioned with the knee at a 90º 
angle136. The thickest part of the leg was measured with a measuring tape136. 
Since in elderly a CC <31cm is a good indicator of muscular depletion and risk of 
undernutrition, the cut-off of 31cm was used to classify nutritional status: 
a) Undernutrition: <31cm; 
b) Normal nutritional status: ≥31cm99. 
 
Edinburgh Feeding Evaluation in Dementia Questionnaire 
Eating problems and disruptive eating behaviours are common in patients with 
dementia, especially in moderate to severe stages29. Food or drink refusal, physical 
disabilities, agnosia, difficulties on chewing and/or swallowing may lead to increased 
risk of malnutrition and its negative health outcomes29,139. 
The EdFED-Q is a scale developed to quantify the frequency of eating behaviours and 
eating problems in patients with dementia through 11 questions140–144. To each question 
the health professional must quantify the frequency of that specific behaviour in 
“0=never”, “1=sometimes” and “2=frequently”139. 
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Although there are no cut-off values regarding this tool, it may allow to predict the need 
for assistance and to prevent low food intake and malnutrition29. 
The EdFED-Q is recommended by ESPEN as a validated tool to recognize problems 
with eating and drinking, helping to plan multidimensional interventions29. 
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Results  
 
Population’s characteristics 
A total of 76 participants (69.7% males) were included on this study in the moment of 
admission, from which 82.9% were parkinsonian syndromes (table 2). No participant 
with motor neuron disease was included. 
 
Neurodegenerative diagnose Frequency (%) 
Parkinsonian syndromes  82.9 (n=63) 
Parkinson’s disease 39.5 (n=30) 
Lewy body dementia 15.8 (n=12) 
Progressive supranuclear palsy 6.5 (n=5) 
Multiple system atrophy 5.3 (n=4) 
Corticobasal degeneration  3.9 (n=3) 
Vascular parkinsonism  2.6 (n=2) 
Non-specified parkinsonian syndrome 9.2 (n=7) 
Dementia syndromes 17.1 (13) 
Alzheimer’s disease 6.6 (n=5) 
Frontotemporal dementia 5.3 (n=4) 
Non-specified dementia syndrome 5.3 (n=4) 
Table 2. Participants’ neurodegenerative diagnoses in the moment of admission. 
Due to the low number of participants with PSP, LBD, MSA, CBD, VP, and non-
specified parkinsonian syndrome, all these diseases were grouped in a single group: 
“Atypical parkinsonism”145.  
Table 3 displays the sociodemographic and clinical data of the participants. 
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All 
participants 
(n=76) 
Parkinsonian syndromes 
(n=63) 
Dementia syndromes 
(n=13) 
p b Parkinson’s 
disease 
(n=30) 
Atypical 
parkinsonism 
(n=33) 
p a 
Atypical parkinsonism diagnoses   
LBD 
(n=12) 
PSP 
(n=5) 
MSA 
(n=4) 
Corticobasal 
degeneration 
(n=3) 
Vascular 
parkinsonism 
(n=2) 
Non-specified 
parkinsonian 
syndrome  
(n=7) 
Alzheimer’s 
disease 
(n=5) 
FTD 
(n=4) 
Non-specified 
dementia 
syndrome 
(n=4) 
Age (years) 76±6.8 75.1±5.5 75.8±7.4 0.681 78.4±8.4 76.6±7.8 72±6.6 74.7±4.0 72.0±1.4 74.6±7.7 80.0±6.6 82.5±10.7 73.0±2.9 0.181 
Gender (female/male) 23/53 7/23  - 2/10 1/4 0/4 1/2 1/1 4/3 4/1 2/2 1/3 - 
Severity of the disease 
Hoehn & Yahr 
Clinical dementia rating 
4 (4) 
2 (2.5) 
3 (4) 
- 
5 (4) 
- 
0.052 * 
- 
4 (4) 
- 
5 (2) 
- 
4.5 (2) 
- 
5 (0) 
- 
4.5 (1) 
- 
5 (3) 
- 
- 
2 (1) 
- 
2.5 (1) 
- 
2 (2.5) 
- 
- 
Frailty 
MCPS 
Clinical Frailty Scale 
38.3±21.0 
3 (5) 
31.8±18.1 
3 (5) 
45.2±22.5 
2 (5) 
0.011 * 
0.312 
43.6±19.9 
2 (4) 
37.6±17.5 
2 (2) 
49.5±21.1 
2 (1) 
76.0±26.9 
2 (1) 
42.0±29.7 
3 (0) 
38.1±23.4 
2 (4) 
26.2±14.8 
3 (3) 
48.3±24.2 
2.5 (1) 
35.0±17.5 
2.5 (2) 
0.761 
0.892 
Nutritional status 
MNA 
SGA 
Body mass index 
Mid-arm circumference 
Calf circumference 
EdFED-Q 
20.3±5.0 
2 (2) 
26.1±5.3 
29.1±4.6 
35.4±4.7 
3.7±3.7 
21.3±4.7 
2 (2) 
26.3±5.1 
29.4±4.4 
35.8±4.5 
2.6±3.4 
19.8±5 
2 (2) 
26.3±5.8 
29.4±4.9 
35.2±4.9 
4.5±4 
0.181 
0.662 
0.691 
0.791 
0.671 
0.011 * 
19.7±4.1 
1.5 (1) 
26.9±7.3 
28.4±5.5 
35.0±5.6 
4.1±3.1 
21.4±3.9 
2 (1) 
26.2±2.6 
31.5±3.1 
37.2±1.5 
2.8±3.1 
17.8±6.6 
1 (1) 
25.9±4.9 
27.0±3.9 
35.0±4.1 
4.8±4.1 
14.3±6.3 
1 (2) 
21.2±5.0 
25.8±2.4 
29.1±7.9 
8.7±6.4 
25.0±0.7 
2 (0) 
31.3±10.3 
28.3±6.1 
34.9±0.9 
1.5±0.7 
20.9±5.3 
2 (2) 
26.4±4.2 
32.7±4.6 
36.8±4.1 
5.4±5.0 
18.6±6.5 
1 (2) 
22.1±2.2 
24.9±3.0 
32.4±3.1 
4.2±1.9 
19.9±6.9 
1.5 (1) 
28.5±6.8 
31.6±4.8 
39.5±4.7 
6.0±4.2 
19.5±3.2 
1.5 (1) 
25.3±2.9 
27.1±3.0 
33.4±2.6 
2.5±1.9 
0.461 
0.402 
0.511 
0.261 
0.521 
0.221 
Table 3. Sociodemographic and clinical data of the participants in the admission moment. 
Mean values ± standard deviation; Median values (interquartile range); MCPS (Marigliano-Cacciafesta Polypathological Scale); MNA (Mini Nutritional Assessment); SGA (Subjective Global 
Assessment); EdFED-Q (Edinburgh Feeding Evaluation in Dementia Questionnaire); LBD (Lewy Body Dementia); PSP (Progressive Supranuclear Palsy); MSA (Multiple Systems Atrophy); 
FTD (Frontotemporal dementia); a p value for the comparison between Parkinson’s disease and atypical parkinsonism groups; b p value for the comparison between parkinsonian and dementia 
syndromes groups ; 1 p value for the Mann-Whitney test for independent samples; 2 p value for the Chi square test for independent samples; * Significant 
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In the first reassessment moment (one-month after the admission), from the 76 initial 
participants, only 22.4% (n=17) participants were included and 82.4% (n=14) of them 
had a parkinsonian syndrome. In the reassessment after 3 months only 7.9% (n=6) 
participants were included, from which 83.3% (n=5) had a parkinsonian syndrome. 
The number of participants included in the reassessment moments diminished since the 
admission moment due to discharge or death. 
 
Frailty  
According to the MCPS and the CFS most of the participants were medium-severely 
frail (46.1%) and severely frail (44.7%), respectively (table 4). 
 
Marigliano-Cacciafesta 
Polypathological Scale (n=76) 
Clinical Frailty Scale (n=76) 
Classification Frequency (%) Classification Frequency (%) 
Slight 6.6 (n=5) Managing well 3.9 (n=3) 
Medium 22.4 (n=17) Vulnerable 9.2 (n=7) 
Medium-severe 46.1 (n=35) Mildly frail 10.5 (n=8) 
Severe 15.8 (n=12) Moderately frail 27.6 (n=21) 
Very severe 9.2 (n=7) Severely frail 44.7 (n=34) 
 Very severely frail 3.9 (n=3) 
Table 4. Frailty frequency according to the Marigliano-Cacciafesta Polypathological Scale and to the 
Clinical Frailty Scale in the moment of admission. 
 
The MCPS score and the CFS classification were statistically significant correlated (rs= 
-0.665; p=0.000). This correlation was stronger in dementia syndromes (rs= -0.773; 
p=0.002), followed by atypical parkinsonism (rs= -0.635; p=0.000) and PD (rs= -0.501; 
p=0.005). 
The frequency of the severity of frailty in the different types of neurodegenerative 
disorder are presented in figure 2.  
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Figure 2. Frequency of the severity of frailty assessed by the Marigliano-Cacciafesta Polypathological Scale (MCPS) 
according to the neurodegenerative disorder (n=76). 
 
The MCPS and the severity of parkinsonian syndromes showed a moderate correlation 
(r=0.451; p=0.000), while no correlation was found between MCPS and the severity of 
dementia (r= 0.321; p=0.285, respectively). 
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Nutritional status 
According to the different nutritional parameters, the frequencies of undernutrition, risk 
of undernutrition, normal nutritional status and overweight or obesity are presented in 
figure 3.  
 
Figure 3. Nutritional status according to the different criteria in the moment of admission (n=76). 
 
 
MNA 
Although, in the admission moment, no statistically significant differences were found 
between parkinsonian and dementia syndromes regarding nutritional status assessed by 
the MNA (table 3), the dementia syndromes group seem to have a higher frequency of 
undernutrition (figure 4). 
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Figure 4. Frequency of nutritional status according to the Mini Nutritional Assessment (MNA) for the different 
neurodegenerative disorders (n=76). 
 
BMI 
Most of the patients with PD were obese (30%), while atypical parkinsonism were more 
frequently normal (30.3%) and dementia syndromes undernourished (23.1%) (figure 
5).  
 
Figure 5. Frequency of nutritional status according to the body mass index (BMI) for the different neurodegenerative 
disorders (n=76). 
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Nutritional status and the severity of the neurodegenerative disease 
Correlations between the severity of dementia syndromes, assessed by the CDR score, 
and nutritional status parameters were not found. 
Regarding the severity of the parkinsonian syndromes, only the MNA (r= -0.394; 
p=0.001), the EdFED-Q (r=0.315; p=0.012) and the SGA (rs= -0.308; p=0.014) 
evidenced a significant, although weak, correlation with H&Y. 
 
Frailty and Nutritional status 
Significant correlations were found between the nutritional assessment parameters and 
the MCPS. The MNA and the EdFED-Q scores both showed a strong correlation with 
the MCPS (table 5). 
 
 
Body mass 
index 
MAC CC MNA EdFED-Q SGA 
MCPS r= -0.363** r= -0.347** r= -0.477** r= -0.732** r= 0.714** rs= -0.437** 
CFS rs=0.227* rs=0.302** rs=0.341** rs=0.629** rs= -0.689** rs=0.507** 
Table 5. Correlations between frailty scales and nutritional parameters.  
MCPS (Marigliano-Cacciafesta Polypathological Scale), CFS (Clinical Frailty Scale), Mid-arm circumference 
(MAC), Calf circumference (CC), Mini Nutritional Assessment (MNA), EdFED-Q (Edinburgh Feeding Evaluation 
in Dementia Questionnaire), Subjective Global assessment (SGA). 
* p<0.05 ** p<0.01  
 
Statistically significant differences between reassessment moments were not found 
regarding the MCPS (figure 6). 
Statistically significant differences between the score of the MNA in the admission 
moment and in the first reassessment moment were found only in parkinsonian 
syndromes (W= -2.524; p=0.012). Between the admission and the three-month 
reassessment no differences were found in the MNA score (figure 6). 
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Figure 6. Comparison between frailty assessed by the Marigliano-Cacciafesta Polypathological Scale (MCPS) and 
nutritional status assessed by the Mini Nutritional Assessment (MNA) in the three assessment moments. 
Wilcoxon test for paired samples * p<0.05 
 
The relation between frailty and BMI in parkinsonian, atypical parkinsonism and 
dementia syndromes is described in figures 7 to 9. 
15
35
55
75
A D M IS S IO N 1  M O N T H  3  M O N T H S
Frailty and nutritional status in the three 
assessment moments
MNA for parkinsonian syndromes
MNA for dementia syndromes
MCPS for parkinsonian syndromes
MCPS for dementia syndromes
* 
 
 
44 
 
 
Figure 7. Relation between frailty and body mass index in parkinsonian syndromes. 
 
Figure 8. Relation between frailty and body mass index in atypical parkinsonian syndromes. 
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Figure 9. Relation between frailty and body mass index in dementia syndromes. 
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Discussion  
Frailty  
In the present study, the frequency of frailty in institutionalized patients with 
neurodegenerative disorders is high (71.1%). 
Due to the lack of studies regarding frailty performed in institutionalized patients with 
neurodegenerative disorders, the comparison of our results was difficult21. However, 
the prevalence found in our study was considerably higher than in previous studies with 
community-dwelling older adults, since the overall prevalence of frailty in 10 European 
countries is 17%19,69. In Portugal, the prevalence of frailty, assessed by the PFP, is 35%, 
mostly in women and in advanced ages146. 
Evidence of the prevalence of frailty in nursing homes is scarce, possibly due to the 
limitations on the application of the screening tools, since most of them requires the 
physical or mental collaboration of the patient, that may be lacking in an 
institutionalization context. The high levels of dependence, comorbidity, disabilities, 
and malnutrition in the long-term care may contribute to this21. 
A systematic review published by Kojima and colleagues regarding 9 studies performed 
with institutionalized elders, estimated a prevalence of 52% frail elders and 40% 
prefrail according to different assessment criteria (PFP, CFS, Edmonton Frail Scale, 
and two others)21. In our institutionalized older adults sample (average age of 76±6.8 
years), the frequency of frailty is considerable higher, and our sample is younger than 
the one found by the systematic review (80.3 years)21. This can evidence that even 
younger, the load of the neurodegenerative disorder can influence the risk and/or 
severity of frailty in this population. However, the clinical characteristics of the 
population pooled by the systematic review were not described21. 
Also, the higher frequency of frailty in our study when compared with other studies 
performed in nursing homes or long-term care institutions, may be related to the 
specific setting were data was collected – an institution specialized in 
neurodegenerative disorders. This means that the majority of the patients had a 
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neurodegenerative condition, which may not be necessarily true for general nursing 
homes that have a more heterogenous population regarding clinical diagnosis. 
Although few studies using the MCPS are published, this tool has been considered 
useful for screening frailty and to programme an intervention/rehabilitation by its 
stratification of the severity of frailty28,147. 
We found that frailty was higher in the dementia group than in parkinsonian syndromes, 
although not statistically significative, independently of the assessment tool. However, 
we found that participants with atypical parkinsonism presented more severe frailty 
than PD, according to the MCPS. Also, the atypical parkinsonism participants presented 
more severe disease than PD. These differences are in concordance with the 
literature148–152. Atypical parkinsonism usually have a faster and more severe 
progression than PD, with a poor response to dopaminergic treatment, worse prognosis, 
shorter survival and more complications in early stages145,152. Motor features such as 
early postural instability and falls, early dysarthria and dysphagia, dystonia, and 
impaired response to levodopa treatment are frequent in atypical parkinsonism, along 
with early and severe cognitive and behavioural changes, apraxia, hallucinations, 
orthostatic hypotension, and urinary dysfunction145. 
In our study, the frequency of frailty in the moment of admission, in patients with 
parkinsonian syndromes in the admission moment was 70.6% (corresponds to the sum 
of medium-severe, severe and very severe frailty). Specifically, in PD the frequency 
was 60% and in atypical parkinsonism was 85.7%.  
In a sample of 133 patients in an acute hospital with an average age of 74 years, the 
frequency of frailty was 75.9%, which is similar to our results although assessed with 
another assessment criteria90. Also, 76.7% of those patients were malnourished and at 
risk of malnutrition90. 
Although moderate, we found a statistically significant correlation between frailty and 
the severity of parkinsonian syndromes. A small number of studies had described the 
prevalence of frailty in PD, and some of them demonstrated that females with PD have 
a higher risk of frailty than males46–48. Also, the severity of PD assessed with the unified 
Parkinson’s disease rating scale and levodopa dose, seem higher in frail patients47,48.  
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The high frequency of frailty found in our study was expectedly high, since some of the 
clinical features of parkinsonian and dementia syndromes are considered major risk 
factors for frailty and are part of several assessment tools. Slow gait speed is a common 
feature of parkinsonian syndromes, along with postural instability, risk of falls and 
balance impairment153–155. Depression, cognitive decline, malnutrition, and urinary 
dysfunction may also occur especially in advance stages156–158. Since most of our 
participants were rated as high severity level of the neurodegenerative disease, this 
frequency seems reasonable.  
 
Nutritional status 
The frequency of undernutrition and the risk of undernutrition according to the MNA 
in our study is also high, and in concordance with a previous study performed in similar 
population (73.7 versus 77.1% respectively72), and, in general, higher than published 
studies in nursing homes or community59,62,68–70,72,159,160.   
Besides the wide variation, depending on the applied methodology, in PD patients the 
general prevalence of malnutrition varies between 0-24% while 3 to 60% are estimated 
to be at risk64. When assessed with the MNA, the variation between studies decreases 
to 0-2% of malnourished and 20-34% at risk64. Our results in PD patients regarding 
undernutrition and risk of undernutrition (66.7%) were similar to the ones obtained in 
a sample of 34 institutionalized PD elders, where 62% were malnourished or at risk at 
the admission according to the MNA72. 
Body weight and PD share a relation that is still unexplained156. Weight loss is frequent, 
especially in advanced stages of the disease, and it has been shown that weight loss and 
low body weight (and BMI) are associated with a higher risk of developing dyskinesia 
due to the higher ratio of levodopa dose per kilogram (>6mg/kg)161. Also, weight loss 
is associated with mortality and poor quality of life71,161. 
The frequency of undernutrition or risk of undernutrition in patients with LBD in our 
study (n=12) was 83.3%, which is higher than the one found by Roque and colleagues 
in a community setting (77.3%)76. 
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Regarding dementia syndromes, 84.6% of the patients were undernourished or at risk 
according to the MNA. Specifically, in AD patients (n=5), 80% was undernourished or 
at risk of undernutrition. Despite the small number of patients with AD included, this 
frequency is higher than the one found in community-dwelling AD elders (varies from 
14.1 to 55.9%)76.  
 
Frailty and Nutritional status 
Interestingly, the general frequency of undernutrition (or risk of) is very similar to the 
frequency of frailty. This goes in favour of the strong correlation between MNA and 
MCPS that was demonstrated in our study (r= -0.732; p<0.01) and in line with previous 
studies regarding the correlation between nutritional status and frailty69,90. The MNA 
assesses several risk factors for frailty, namely weight loss and low BMI, reduced 
mobility, and low nutritional intake. In the parkinsonian syndromes, the undernourished 
participants were also the ones with more severe frailty while the patients at risk of 
undernutrition were also medium-severely frail. In dementia syndromes similar 
tendency was verified. 
On the other hand, the correlation between BMI and MCPS was weak (r= -0.363; 
p<0.01). In the MCPS, nutritional status can be assessed with the MNA or the BMI, 
however the considered BMI cut-offs are commonly used for adults and not for elders. 
This means that an elder can be mistakenly considered overweight instead of normal 
since the reference value for normal in older adults is 24-26.9kg/m2 that is close to 
overweight cut-offs in adults (25-29.9kg/m2). Despite this, in our study we also found 
a U-shaped relation between frailty and BMI78,79,83. This relation was more obvious in 
parkinsonian syndromes than in dementia syndromes possibly due to the differences in 
the number of participants in both groups.  
 
Since frailty is considered a dynamic state and reversible in some of its components, 
we performed a comparison between the admission moment and one-month after. 
Although the differences were not statistically significant, is evident that the severity 
of frailty tends to increase one month after the admission in the parkinsonian syndromes 
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group. Despite the low number of remaining patients to the reassessment, this may be 
related to the high severity of the disease in the admission, the lack of some clinical 
information that were only diagnosed after the first 48 hours of admission (and thus, 
not considered for the frailty assessment in the admission moment but only in the 
reassessment) such as the presence of hiper- or hypotension, and the unknown 
neurological diagnose (regarding patients that could be admitted for diagnostic 
investigation). 
Parkinsonian syndromes are degenerative conditions that, especially in advanced stages 
or in atypical parkinsonisms, can have a faster progression, higher severity, and higher 
rates of physical dependence76,145,152. Also, the management of parkinsonian syndromes 
is difficult, especially in more advanced stages of the disease, and takes time for 
pharmacological treatment to be adjusted to achieve a balance of motor and/or non-
motor control and functionality162–164. 
On the other hand, dementia syndromes tended to decrease the severity of frailty since 
the admission. Behaviour changes, food refusal and severe feeding difficulties are 
common in dementia patients, especially in more advanced stages29,165. In our study, 
feeding difficulties were more frequent in dementia than in parkinsonian syndromes in 
the admission moment, however in the one-month reassessment this frequency 
decreased in dementia syndromes along with the decreasing in the severity of frailty 
and improved nutritional status. Since the correlation between the MCPS, the MNA 
and the EdFED-Q is strong this may justify the improvement of frailty in this group in 
the reassessment moment.  
In general, we can notice the institutionalization seems to contribute to improve the 
nutritional status of both parkinsonian and dementia syndromes. Regarding frailty, an 
increase on its severity in parkinsonian syndromes tends to appear despite of a slight 
improvement on nutritional status.   
The timing to reassess these patients may had been short to see changes in frailty, due 
the complexity of these diseases and significant changes on some domains of the MCPS 
may take longer than one or three-months. 
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Limitations 
Our study has some limitations. First, the low number of participants included in the 
reassessment moments. Second, the unbalanced proportion of participants with 
parkinsonian and dementia syndromes. 
 
The initial research protocol previewed the application of the PFP criteria, however due 
to the level of collaboration needed to perform this assessment only a few number of 
participants would be able to complete it since most were in severe stages of the 
diseases. Also, the PFP validation study specifically excluded patients with the 
neurodegenerative disorders that we aimed studying10.  
The study of the clinimetric properties of the MCPS were predicted but not feasible due 
to the insufficient sample size166. 
As a tool for frailty assessment, the MCPS is, in our point of view, comprehensive in 
most of the described risk factors for frailty, objective, and stratifies the severity of 
frailty. Also, when compared with other tools, the MCPS has the advantage of not being 
dependent on the patients’ collaboration to be fulfilled. 
The MCPS is a complex multidomain tool to be applied by a single health professional 
meaning that a multidisciplinary filling would be preferable to more accurately assess 
frailty in all its domains.  
On the other hand, the MCPS also has also some limitations. The scale, although 
comprehensive, lacks on some specifics. For instance, in the renal disorders section, 1 
point should be attributed if the patient present rare episodes of urinary incontinence; 
however, if the patient have urinary incontinence there is no correspondent score. In 
this case, the investigators considered a 10-point score that corresponds to the next level 
of severity in this item. In the metabolism and nutritional state item, the MCPS adds, in 
comparison to other tools, the possibility to consider higher BMI as a severity 
component for frailty. However, the cut-off values for BMI are for adults and not 
specifically for elders over 65 years old. This can influence the results when trying to 
correlate the MCPS with BMI. Also, in some situations the investigator is confronted 
with patients with a normal MNA score (≥23.5 points) but a BMI of 26kg/m2 that would 
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be considered by the scale as overweight. In this case, we must choose which 
parameters matters the most leading to subjectivity and possibly to inter-ratter’s 
variability.   
Based on our results, the MCPS could be a useful tool to assess and stratify the severity 
of frailty in institutionalized older adults. Future research should be performed to 
validate this tool and an analysis on which specific domains from the MCPS are the 
major contributors to frailty and which ones are changeable by intervention. 
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Conclusions 
The frequency of frailty in institutionalized patients with neurodegenerative disorders 
is, as expected, high. Similar frequency of undernutrition (or risk of) was found. 
Nutritional status and frailty seem to be significantly correlated. Since inadequate 
nutrition and/or poor nutritional status are potentially treatable causes for frailty, it 
seems reasonable to further investigate the effects of therapeutic nutritional 
interventions to prevent and to treat frailty. 
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Annex I – Information sheet 
Folha de Informação para os participantes 
Título do projecto de investigação 
Fragilidade e estado nutricional em utentes com doenças neurodegenerativas. 
Objectivo do estudo 
O objetivo principal do estudo é descrever a frequência da fragilidade em indivíduos com 
doenças neurodegenerativas na admissão de uma instituição de saúde. Os objetivos secundários 
são descrever a frequência da desnutrição, avaliar a correlação entre o estado nutricional e a 
fragilidade na admissão e comparar a frequência da desnutrição e fragilidade um a três meses 
após a institucionalização. 
Procedimento 
Na admissão da instituição, será avaliada a fragilidade (através de 3 escalas) e o estado 
nutricional (através de medições antropométricas e 2 escalas). Se possível, 1 a 3 meses após a 
admissão serão reaplicados os mesmos procedimentos para comparação. 
Possíveis benefícios para os participantes 
Se concordar em participar, não terá nenhum benefício clínico direto. Contudo, a sua 
participação poderá contribuir para o aumento do conhecimento sobre a fragilidade e estado 
nutricional de utentes com doenças neurodegenerativas, o que poderá beneficiar os doentes ou 
terceiros no futuro. Não receberá nenhuma compensação económica pela sua participação neste 
estudo. 
Riscos físicos previsíveis 
Não está previsto qualquer risco decorrente da participação neste estudo.  
Participação voluntária e direitos de abandono 
Se concordar em participar, a qualquer momento pode desistir e solicitar que os dados 
recolhidos neste estudo sejam eliminados sem qualquer consequência para si. 
Utilização dos dados 
Se assinar este consentimento, dará permissão ao investigador principal envolvido neste estudo, 
bem como aos seus orientadores, para que utilizem informações demográficas, adequadamente 
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anonimizadas. A informação usada neste estudo, e que poderá ser divulgada, inclui dados que 
serão anonimizados, de forma a que não seja possível associar a identidade às avaliações e aos 
dados demográficos. A futura apresentação e publicação dos resultados do estudo respeitará 
sempre a confidencialidade dos dados e o anonimato dos participantes. 
 
Contatos  
Poderá contactar a investigadora principal do estudo, Mestranda Diana Miranda para responder 
a qualquer dúvida que tenha relativamente ao estudo e à sua participação no mesmo.  
Contacto telefónico: 917 151 826 
Email: diana.santos.miranda@gmail.com 
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Annex II – Informed consent 
Fragilidade e estado nutricional em indivíduos com doenças neurodegenerativas 
Informação aos participantes 
A fragilidade é uma síndrome caracterizada por um estado de vulnerabilidade 
aumentada a qualquer mudança ou acontecimento mínimo de stress, que pode contribuir para 
o comprometimento da independência e qualidade de vida dos doentes. O estado nutricional 
parece ter um papel importante no desenvolvimento da fragilidade. 
A pertinência do estudo que propomos prende-se com o esclarecimento da frequência 
da fragilidade e relação entre a fragilidade e o estado nutricional em indivíduos com doenças 
neurodegenerativas. 
Ao aceitar participar, serão preenchidas três escalas de avaliação da fragilidade e duas 
escalas de avaliação do estado nutricional. Adicionalmente serão recolhidos e registados o peso, 
altura, perímetro da perna e perímetro do braço. Estes dados serão recolhidos na admissão, um 
mês e três meses após a admissão.  
Todos os dados sociodemográficos e clínicos colhidos serão armazenados de forma 
codificada, de modo a proteger os seus dados pessoais. Em nenhuma ocasião, o seu nome 
figurará nos documentos finais de estudos ou em publicações científicas dos resultados.  
Caso decida não participar, quer antes de iniciar os procedimentos do estudo, quer a 
meio, não será prejudicado. Para tal, basta comunicar-nos a sua decisão e todos os seus dados 
pessoais que tenham sido recolhidos serão apagados de forma definitiva. 
Agradecemos desde já a sua colaboração e vontade em participar. 
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Consentimento informado 
 
Eu, abaixo assinado, aceito participar no estudo intitulado “Fragilidade e estado nutricional em 
indivíduos com doenças neurodegenerativas” 
 
Nome completo _______________________________________________ 
Data   ______________ 
 Assinatura    _________________________________________________ 
       *No caso de participantes com compreensão comprometida 
      Responsável Legal*  ___________________________________ 
       Testemunha*   ________________________________________ 
 
A preencher pelo investigador que fornece o consentimento informado: 
                     Data______________ Instituição   _______________________ 
   Assinatura__________________________________________ 
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Fragilidade e estado nutricional em indivíduos com doenças neurodegenerativas 
Consentimento informado para o centro de investigação 
Eu, abaixo assinado, aceito participar no estudo intitulado “Fragilidade e estado nutricional em 
indivíduos com doenças neurodegenerativas” 
Nome completo ______________________________________________ 
Data   __________________    
 Assinatura    _________________________________________________ 
      *No caso de participantes com compreensão comprometida 
    
      Responsável Legal*    Nome   ____________________________ 
     Assinatura __________________________ 
       Testemunha*              Nome _____________________________ 
               Assinatura__________________________ 
 
A preencher pelo investigador que fornece o consentimento informado: 
                     Data______________ Instituição   _______________________ 
   Assinatura__________________________________________ 
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Annex III – Case report form 
Frailty and nutritional status in patients with neurodegenerative 
disorders - CRF 
Subject ID (CNS number):  
Date of admission: ___/___/______    Date of assessment: ____/____/______ 
 
A) General features 
 Age, years:                    Gender:  
 Weight, kg:                    Height, cm: 
 Main neurodegenerative disorder: __________________________________ 
 Medical history clinical background: ______________________________________ 
_____________________________________________________________________
_____________________________________________________________________ 
 If PD patients, Hoehn & Yahr:  
 If dementia patients, CDR:  
 
B) Outcome assessment scales  
1) Nutritional Assessment  
1.1) Mini Nutritional Assessment Full-Form (MNA-FF) score: 
 
1.2) Subjective Global Assessment (SGA) score: 
 
1.3) Body Mass Index (kg/m2): ________ (Classification: ____________________) 
 
1.4) Calf circumference (cm): ________ 
 
1.5) Mid-arm circumference (cm): _________ (1988-1994 CDC percentile: _______) 
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1.3) Edinburgh Feeding Evaluation in Dementia Questionnaires (EdFED-Q)  
 
A) O doente necessita de supervisão 
próxima durante a refeição? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente  
 
B) O doente necessita de apoio físico para 
a realização da refeição? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente 
 
C) Existe derrame durante a refeição? 
0 = Nunca  
1 = Às vezes 
2 = Frequentemente  
 
D) O doente tende a deixar comida no 
prato no final da refeição? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente  
 
E) Alguma vez o doente recusa alimentar-
se? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente  
 
F) O doente vira a cara enquanto está a ser 
alimentado? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente  
 
G) O doente recusa-se a abrir a boca? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente 
 
H) O doente cospe a comida? 
0 = Nunca  
1 = Às vezes 
2 = Frequentemente 
 
I) O doente permanece de boca aberta 
permitindo que a comida caia? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente 
 
J) O doente recusa-se a engolir? 
0 = Nunca  
1 = Às vezes  
2 = Frequentemente 
 
Total Score: ________ 
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2) Frailty 
 
2.1) The Marigliano-Cacciafesta polypathological scale 
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Total score: 
Slight polypathology <15 scores  
Medium polypathology 15-24 scores  
Medium-severe polypathology 25–49 scores  
Severe polypathology 50–74 scores  
Very severe polypathology >75 scores  
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2.2) Clinical Frailty Scale 
Score: ______ 
 
2.3) Physical Frailty Phenotype (Fried) 
 
